



Project title: “On the road to excellence in unravelling the (epi)genetic landscape of hematologic neoplasms” - NEXT\_LEVEL  
 Grant agreement No 952304

	<b>Topic</b>	<b>Principal Investigator - Partners</b>	<b>Principal Investigator - IHG PAS</b>
1	Mechanisms of somatic manifestation of germline predisposition to B-cell lymphomas (cHL, NHL) (including epigenetics, eQTLs, etc)	Arjan Diepstra (UMCG) Reiner Siebert (UUIM)	Agnieszka Dzikiewicz - Krawczyk (focus on variation in non-coding sequences)
2	Small RNAs, ncRNAs and circRNAs in lymphoid neoplasms: From expression profiling to functional characterization	J.L. (Joost) Kluiver (UMCG) Pieter van Vlierberghe (UGent)	Małgorzata Dawidowska (microRNAs) Maciej Giefing (microRNAs) Agnieszka Dzikiewicz – Krawczyk (lncRNA, eRNA)
3	Transcription factor expression and function in lymphoid neoplasms: from MYC, MYB, ETS family and SOX11 to IG expression	J.L. (Joost) Kluiver (UMCG) Pieter van Vlierberghe (UGent)	Maciej Giefing Agnieszka Dzikiewicz- Krawczyk
4	Interplay between genomics and epigenomics in T-cell leukemias (T-ALL and T-PLL)	Pieter van Vlierberghe (UGent) Julia Vogt (UUIM)	Małgorzata Dawidowska
5	Molecular pharmacology in lymphoid neoplasms (cardiotoxicity of chemo agents)	Lydia Visser (UMCG), Pieter van Vlierberghe (UGent)	Natalia Rozwadowska
6	Liquid Biopsies in (but not restricted to) cHL: Mutational-, Chromosomal and Epigenomic Profiles	Anke van den Berg (UMCG) Ole Ammerpohl (UUIM)	Maciej Giefing Małgorzata Dawidowska



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 952304